Skip to main content

Market Overview

Zai Lab's Niraparib Shows 3X Longer PFS Compared to Placebo In Ovarian Cancer

Share:
Zai Lab's Niraparib Shows 3X Longer PFS Compared to Placebo In Ovarian Cancer

Zai Lab Limited (NASDAQ: ZLABpresented data from the Phase 3 PRIME study of Zejula (niraparib) as maintenance therapy in Chinese ovarian cancer patients.

  • Zejula demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with a tolerable safety profile with newly diagnosed ovarian cancer following response to platinum-based chemotherapy, regardless of biomarker status.
  • The median Progression-free survival (PFS) was significantly longer for patients treated with niraparib than placebo: 24.8 months versus 8.3 months.
  • Overall survival data are still immature (percentage of death in niraparib and placebo groups are 14.5% vs. 21.7%); there is a trend in favor of niraparib at the data cut-off.
  • The safety profile of niraparib was improved with the individualized starting dosing (ISD) prospectively applied to all patients. 
  • In December 2021, the National Reimbursement Drug List (NRDL) released by China's National Healthcare Security Administration (NHSA) was updated to include Zejula as a first-line maintenance treatment of ovarian cancer.
  • Price Action: ZLAB shares traded lower by 1.63% at $38.10 on the last check Monday.
 

Related Articles (ZLAB)

View Comments and Join the Discussion!

Posted-In: Briefs Ovarian Cancer Phase 3 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com